GLP-1 Prescriptions for Children Ages 8–11 Surge 310-Fold Since 2019
Source Summary
A large cross-sectional analysis found that GLP-1 receptor agonist prescriptions for children ages 8 to 11 with obesity increased 310-fold since 2019, despite lacking FDA approval in children under 12. The study examined data from over 3.5 million children.
Why it matters
The dramatic increase in off-label GLP-1 use in young children raises questions about safety and efficacy in an unapproved age group.
